Delivery Order SPE2DB24D3013-SPE2DB25FFHSD

Award Date 1/3/25
Potential Completion Date 1/6/25
Potential Value $3.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order with a firm fixed price of $3,820.10 and a completion date of November 19, 2024. The contract is for the supply of the drug WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. This award is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $15,378.49 and a completion date of January 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is a delivery order under Amerisourcebergen Drug Corp's Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 through December 31, 2025. The specific order is for the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML, with a ceiling value of $12,103.36. This delivery order does not have a set-aside designation. Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, is the...
This is a delivery order under a larger indefinite delivery contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract has a potential value of $999,999,999.00 and a performance period through December 31, 2025. The delivery order is for the pharmaceutical product WEGOVY 1 MG/0.5 ML PEN 0.5ML, with a ceiling value of $1,894.34 and a firm fixed price. No set-aside designation was...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $25,836.67 for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of December 27, 2024. This contract award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a firm fixed price delivery order awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, by the Defense Logistics Agency (DLA) Troop Support Medical. The order is for the pharmaceutical product WEGOVY 1.7 MG/0.75 ML PEN 0.75ML, with a ceiling value of $3,772.94 and a performance period ending on April 5, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, valued at up to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,468.42 and a period of performance through January 11, 2024. It is a firm fixed-price contract, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,228.50 Firm Fixed Price delivery order is for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML, a specialty medication. The award has an ultimate completion date of December 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML, a specialty medication. The contract has a firm fixed price of $3,958.20 and is set to expire on September 25, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which allows the agency...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract has a ceiling value of $2,593.50 and a completion date of January 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFHSD
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of a pharmaceutical product, WEGOVY 1 MG/0.5 ML PEN 0.5ML, with a ceiling value of $3,229.59 and a completion date of January 6, 2025.

The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/4/25, 9:55 AM